Press Releases

 
Press Releases
  Date Title View
Nov 9, 2017
BERKELEY, CA -- (Marketwired) -- 11/09/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. HEPLIS...
Nov 3, 2017
BERKELEY, CA -- (Marketwired) -- 11/03/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2017. Cash, cash equivalents and marketable securities were $191.7 million at September 30, 2017 compared to $81.4 million at December 31, 2016. The increase was primarily due to ne...
Oct 19, 2017
BERKELEY, CA -- (Marketwired) -- 10/19/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced initiation of dosing in a phase 1B dose escalation clinical trial of its investigational inhaled toll-like receptor 9 (TLR9) agonist, DV281, in patients with non-small cell lung cancer (NSCLC). This multi-center, open label trial is designed to e...
Sep 5, 2017
BERKELEY, CA -- (Marketwired) -- 09/05/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the company will present at two upcoming investor conferences in September. NewsMakers in the Biotech Industry Investor ConferenceFriday, September 8, 2017 in New York at 8:30 a.m. Eastern Time ...
Aug 15, 2017
BERKELEY, CA -- (Marketwired) -- 08/15/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the completion of an underwritten public offering of 5,750,000 shares of its common stock, including 750,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters. All of the shares wer...
Aug 9, 2017
BERKELEY, CA -- (Marketwired) -- 08/09/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the pricing of a previously announced underwritten public offering of 5,000,000 shares of its common stock, offered at a price to the public of $15.00 per share. The gross proceeds to Dynavax from this offering are expected to be approximat...
Aug 8, 2017
BERKELEY, CA -- (Marketwired) -- 08/08/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it intends to offer and sell $125.0 million of shares of its common stock, subject to market and other conditions, in an underwritten public offering. Dynavax also expects to grant the underwriters a 30-day option to purchase up to an a...
Aug 3, 2017
BERKELEY, CA -- (Marketwired) -- 08/03/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration (FDA) has requested more detailed information about the company's proposed post-marketing study for HEPLISAV-B™ [Hepatitis B Vaccine, Recombinant (Adjuvanted)] based on feedback received from...
Aug 2, 2017
BERKELEY, CA -- (Marketwired) -- 08/02/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter ended June 30, 2017. Cash, cash equivalents and marketable securities were $127.0 million at June 30, 2017 compared to $81.4 million at December 31, 2016. The increase was primarily due to net proceed...
Jul 28, 2017
BERKELEY, CA -- (Marketwired) -- 07/28/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 12 to 1 that the safety data for HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] support licensure for...
1
...
NextLast
= add release to Briefcase